No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study
Open Access
- 1 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Pharmacogenomics and Personalized Medicine
- Vol. ume 14, 229-237
- https://doi.org/10.2147/pgpm.s281645
Abstract
Background: The use of pharmacogenomics data is increasing in clinical practice. However, it is unknown if pharmacogenomics data can be used more broadly to predict outcomes like hospitalization or emergency department (ED) visit. We aim to determine the association between selected pharmacogenomics phenotypes and hospital utilization outcomes (hospitalization and ED visits). Methods: This cohort study utilized 10,078 patients from the Mayo Clinic Biobank in the RIGHT protocol with sequence and interpreted phenotypes for 10 selected pharmacogenes including CYP2D6, CYP2C9, CYP2C19, CYP3A5, HLA B 5701, HLA B 5702, HLA B 5801, TPMT, SLCO1B1, and DPYD. The primary outcome was hospitalization with ED visits as a secondary outcome. We used Cox proportional hazards model to test the association between each pharmacogenomics phenotype and the risk of the outcomes. Results: During the follow-up period (median [in years] = 7.3), 13% (n=1354) and 8% (n=813) of the subjects experienced hospitalization and ED visits, respectively. Compared to subjects who did not experience hospitalization, hospitalized patients were older (median age [in years]: 67 vs 65), poorer self-rated health (15% vs 4.7% for fair/poor), and higher disease burden (median number of chronic conditions: 7 vs 4) at baseline. There was no association of hospitalization with any of the pharmacogenomics phenotypes. The pharmacogenomics phenotypes were not associated with disease burden, a well-established risk factor for hospital utilization outcomes. Similar findings were observed for patients with ED visits during the follow-up period. Conclusion: We found no association of 10 well-established pharmacogenomics phenotypes with either hospitalization or ED visits in this relatively large biobank population and outside the context of specific drug use related to these genes. Traditional risk factors for hospitalization like age and self-rated health were much more likely to predict hospitalization and/or ED visits than this pharmacogenomics information.Keywords
This publication has 50 references indexed in Scilit:
- Redesigning Primary Care: A Strategic Vision To Improve Value By Organizing Around Patients’ NeedsHealth Affairs, 2013
- History of the Rochester Epidemiology Project: Half a Century of Medical Records Linkage in a US PopulationMayo Clinic Proceedings, 2012
- Generalizability of Epidemiological Findings and Public Health Decisions: An Illustration From the Rochester Epidemiology ProjectMayo Clinic Proceedings, 2012
- Emergency Department Visits for Overdoses of Acetaminophen-Containing ProductsAmerican Journal of Preventive Medicine, 2011
- What Is Value in Health Care?The New England Journal of Medicine, 2010
- Use of an electronic administrative database to identify older community dwelling adults at high-risk for hospitalization or emergency department visits: The elders risk assessment indexBMC Health Services Research, 2010
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCIJAMA, 2010
- The influence of neighborhood environment on the incidence of childhood asthma: A propensity score approachJournal of Allergy and Clinical Immunology, 2010
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987